Analysts Anticipate ARMO BioSciences (ARMO) to Post -$0.45 EPS

Equities analysts forecast that ARMO BioSciences (NASDAQ:ARMO) will report earnings per share (EPS) of ($0.45) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for ARMO BioSciences’ earnings. The lowest EPS estimate is ($0.78) and the highest is ($0.12). The company is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that ARMO BioSciences will report full-year earnings of ($2.68) per share for the current year, with EPS estimates ranging from ($5.14) to ($0.49). For the next year, analysts anticipate that the business will report earnings of ($2.27) per share, with EPS estimates ranging from ($2.83) to ($1.56). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow ARMO BioSciences.

How to Become a New Pot Stock Millionaire

ARMO has been the topic of a number of research analyst reports. Robert W. Baird assumed coverage on ARMO BioSciences in a research note on Tuesday, February 20th. They issued an “outperform” rating and a $67.00 target price on the stock. Leerink Swann upgraded shares of ARMO BioSciences from a “market perform” rating to an “outperform” rating and set a $50.00 price target for the company in a research report on Tuesday, March 27th. BMO Capital Markets assumed coverage on shares of ARMO BioSciences in a research report on Tuesday, February 20th. They set an “outperform” rating and a $75.00 price target for the company. Finally, Jefferies Group assumed coverage on shares of ARMO BioSciences in a research report on Tuesday, February 20th. They set a “buy” rating and a $61.00 price target for the company.

ARMO traded down $0.69 during trading on Wednesday, reaching $36.72. The stock had a trading volume of 65,792 shares, compared to its average volume of 240,376. ARMO BioSciences has a one year low of $27.00 and a one year high of $57.19.

ILLEGAL ACTIVITY WARNING: “Analysts Anticipate ARMO BioSciences (ARMO) to Post -$0.45 EPS” was reported by Enterprise Leader and is owned by of Enterprise Leader. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://theenterpriseleader.com/2018/04/02/analysts-anticipate-armo-biosciences-armo-to-post-0-45-eps.html.

ARMO BioSciences Company Profile

ARMO Biosciences, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company’s platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects that induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in cancer patients.

Get a free copy of the Zacks research report on ARMO BioSciences (ARMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ARMO BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARMO BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply